Key facts
- Huadao Biopharma’s last known valuation is $79.9M (Jul 2019).
- It has raised $58.8M; the latest was Later Stage VC ($14.0M) in Oct 2025.
- Notable investors include Hankang Capital, Shanghai Songjiang State-owned Assets Investment, Jiaxing Jiarui Investment Management, Zhejiang Haiyue Asset Management, Chongqing Technology Venture Capital — 20 tracked in total.
- Status: Privately Held (backing).
Investors
20+- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Huadao Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Huadao Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huadao Biopharma
Developer of cell immunotherapy technology designed for oncology. The company develops CAR-T (chimeric antigen receptor-T) cell technologies including bacteria fermentation engineering, virus purification technique, T cell acquisition, and cell harvesting, providing healthcare practitioners with research resources and expertise to treat acute lymphoblastic leukemia and related diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 83
- Website
- huadaocart.com/
- Ownership
- Privately Held (backing)
Huadao Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huadao Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huadao Biopharma in its N-PORT filings yet. We sweep new filings monthly.